leadf
logo-loader
viewReckitt Benckiser Group PLC
(
LSE:RKTFRA:3RBETR:3RB
)

Reckitt Benckiser: Are the shares worth buying ahead of the company's investor day? Here's what one Wall Street bank thinks

JP Morgan recognised July’s interim results were disappointing but said there were two short-term potential catalysts that could lift the stock

Reckitt Benckiser Group PLC - Reckitt Benckiser: Are the shares worth buying ahead of the company's investor day? Here's what one Wall Street bank thinks

A leading Wall Street bank has reiterated its bullish stance of Reckitt Benckiser Group PLC (LSE:RKT, FRA:3RB, ETR:3RB) ahead of the investor day next week.

JP Morgan recognised July’s interim results were disappointing but said there were two short-term potential catalysts that could lift the stock, which has languished over the last six weeks.

It pointed out that industry sales data is currently supportive of Reckitt hitting or even surpassing its like-for-like sales target.

At the same time, JPM expects “an incremental positive” from the consumer goods giant's strategic review, details of which may be relayed to the wider investing audience at an investor day on September 23.

In a note to clients, it said it would be looking out for “progress on the turnaround journey, the improved capabilities in areas such as innovation, supply chain, execution as well as detailing progress on specific business areas and on return on investments”.

Repeating its ‘overweight’ stance, the investment bank said Reckitt is worth £85 a share. The stock closed the session at £59.16, up 1.65%.

Quick facts: Reckitt Benckiser Group PLC

Follow
LSE:RKT

Price: 5780 GBX

Market Cap: £41.28 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma's hail 'win win deal' as China partner begins programme with...

Destiny Pharma PLC (AIM:DEST) (AIM:DEST) Neil Clark talks to Proactive London about their partner in China, Hong Kong listed China Medical System Holdings (HKG:0867) (HKG:0867) Ltd (CMS) launching a new programme aimed at delivering a new product using Destiny’s XF-73.  Their aim differs to...

7 hours, 53 minutes ago

2 min read